Filtered By:
Vaccination: Vaccines

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 755 results found since Jan 2013.

Evaluation of Allergic Reactions following COVID - 19 Vaccination in Patients with Documented Allergies
CONCLUSION: No patient fitting contraindications for COVID-19 vaccination laid down by the Indian government developed any allergic reaction post vaccination. The guidelines for vaccination may be revisited to make them more inclusive with appropriate training of the vaccination centre staff.PMID:34781647
Source: Journal of the Association of Physicians of India - November 16, 2021 Category: General Medicine Authors: Sunita Chhapola Shukla Sukant Pandit Dhruve Soni Nithya J Gogtay Source Type: research

To mix or not to mix in allergy immunotherapy vaccines
Purpose of review European and US allergists generally do not agree on the approach to subcutaneous allergy immunotherapy in patients with multiple allergies. The North American approach is to treat with a mixture that contains all the allergen extracts to which the patient has evident clinical sensitivity, whereas the European approach is to select for treatment the one or at the most two allergens that are clinically most important for the patient. Recent findings Recent society guidelines continue to recommend these differing practices of treating the polyallergic patient and reviews of prescribing practices ...
Source: Current Opinion in Allergy and Clinical Immunology - November 8, 2021 Category: Allergy & Immunology Tags: IMMUNOTHERAPY AND NEW TREATMENTS: Edited by Giovanni Passalacqua and Robert Bush Source Type: research

Update to COVID-19 chapter of the green book (chapter 14a), UK Health Security Agency (updated 29th October 2021)
Coronavirus (COVID-19) vaccination information for public health professionals. 29 October 2021Updated to improve consistency of wording in the allergy and immunosuppressed sections; updated definitions of clinically vulnerable, advice on further doses for those who have suspected myocarditis or Guillain-Barr é Syndrome after vaccination, clarifying flexibility around the booster timing and supply, additional evidence on booster dose effectiveness and on vaccination after monoclonal antibody products. 16 September 2021Updated to include new recommendations on boosters and children and young people. Minor updates to gu...
Source: Current Awareness Service for Health (CASH) - November 1, 2021 Category: Consumer Health News Source Type: news

Adverse events report of inactivated COVID-19 vaccine from 4040 healthcare workers
CONCLUSION: It is extremely important to identify and document the VAEs occurring in the early postvaccination period in different groups of the community. These initial findings may provide reassurance to healthcare providers and vaccine recipients and promote confidence in the safety of this inactive COVID-19 vaccine, however longitudinal follow-up studies are recommended.PMID:34705583 | DOI:10.1080/00325481.2021.1999708
Source: Postgraduate Medicine - October 27, 2021 Category: Internal Medicine Authors: Selma Tosun H ülya Ozkan Ozdemir Esin Erdogan Seniz Akcay Murat Aysin Neslihan Eskut P ınar Ortan Burak Eskut Source Type: research

COVID Vaccination Can Be Safe Even in People With Severe Allergies
Title: COVID Vaccination Can Be Safe Even in People With Severe AllergiesCategory: Health NewsCreated: 10/26/2021 12:00:00 AMLast Editorial Review: 10/27/2021 12:00:00 AM
Source: MedicineNet Allergies General - October 27, 2021 Category: Allergy & Immunology Source Type: news

COVID-19 vaccines safe for people with history of severe allergies, study finds
People with a history of severe allergic reactions to drugs and vaccines can receive both doses of the two-shot COVID-19 inoculations safely, a study published Tuesday by JAMA Network Open found.
Source: Health News - UPI.com - October 26, 2021 Category: Consumer Health News Source Type: news

U.S. CDC Advisory Committee Unanimously Recommends Johnson & Johnson COVID-19 Vaccine as a Booster for All Eligible Individuals Who Receive Authorized COVID-19 Vaccines
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson & Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson & Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer at Jo...
Source: Johnson and Johnson - October 21, 2021 Category: Pharmaceuticals Source Type: news

Johnson & Johnson COVID-19 Vaccine Booster Shot Authorized for Emergency Use by U.S. FDA
NEW BRUNSWICK, N.J., October 20, 2021 – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson & Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson & Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson & Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendat...
Source: Johnson and Johnson - October 20, 2021 Category: Pharmaceuticals Tags: Latest News Source Type: news

Safety and side effect profile of Pfizer-BioNTech COVID-19 vaccination among healthcare workers: A tertiary hospital experience in Singapore
CONCLUSION: The side effects experienced after Pfizer-BioNTech COVID-19 vaccines are generally self-limiting and mild, with no anaphylaxis reported.PMID:34625758 | DOI:10.47102/annals-acadmedsg.2021160
Source: Ann Acad Med Singapo... - October 9, 2021 Category: General Medicine Authors: See Ming Lim Hwang Ching Chan Amelia Santosa Swee Chye Quek Eugene Hern Choon Liu Jyoti Somani Source Type: research